Loading the records…
Loading the records…
HR6609 is an early-stage bill that would mandate rebate pass-throughs and ban patient steering by PBMs in Medicare and Medicaid. The bill has 36 cosponsors but remains in committee since December 2025 with no further action — legislative probability is low near-term. Despite real headwinds for CVS, CI, UNH, and ELV, the market has rallied these names 3-10% in the past week and 8-42% in 30 days on unrelated earnings and sector rotation, not this bill.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Current prices ($CVS $83.3, $CI $287.69, $UNH $367.09, $ELV $372.94) reflect no material discount for HR6609 risk. The market is correctly assessing this as a low-probability, early-stage bill with a distant effective date (2027). However, if the bill gains unexpected momentum (e.g., committee markup scheduled, new cosponsor wave, Senate companion introduced), expect immediate repricing of these tickers to the downside by 2-5%. For now, the broader tailwinds (earnings, sector rotation) dominate price action. Investors should monitor Committee on Energy and Commerce calendar for any hearing or markup announcement — that would be the first real signal of legislative movement.
WHAT HAPPENED: On December 11, 2025, Rep. Auchincloss (D-MA) introduced HR6609, the 'Pharmacists Fight Back in Medicare and Medicaid Act'. The bill would amend the Social Security Act to require PDP sponsors and their PBMs in Medicare Part D and Medicaid to pass through 100% of manufacturer rebates to the plan at the point of sale, and prohibit steering patients to PBM-owned or affiliated pharmacies. It has 36 cosponsors (bipartisan) and was referred to the Energy & Commerce and Ways & Means Committees. There have been zero actions since referral — the bill is stalled in early-stage committee review.
THE MONEY TRAIL: This bill authorizes no direct government spending. It is a regulatory mandate — it imposes compliance requirements on private entities (PBMs and health plans). The financial impact is a transfer of value from PBM margins to plan sponsors, beneficiaries (lower cost-sharing), and independent pharmacies. For the affected PBMs, the revenue impact is the loss of rebate spreads (estimated 1-3% of drug spend) and steering-related pharmacy profits. No appropriation is involved.
STRUCTURAL WINNERS AND LOSERS: Losers are the vertically integrated PBMs: CVS (Caremark, $83.3), CI (Express Scripts, $287.69), and UNH (Optum Rx, $367.09) — these derive significant profit from rebate retention and steering. ELV ($372.94) is less exposed as it lacks a large captive PBM but still faces compliance costs. Winners would be independent pharmacies (not publicly traded in aggregate) and potentially retail pharmacy chains not affiliated with major PBMs (Rite Aid, if still public; Walgreens ($WBA)). The bill does not directly benefit drug manufacturers.
MARKET DATA REALITY: Despite this legislative overhang, all four tickers have rallied strongly over the past 30 days: CVS +15.98%, CI +7.85%, UNH +35.66%, ELV +27.39%. Over 7 days: CVS +6.88%, CI +4.37%, UNH +3.43%, ELV +8.17%. These moves coincide with broader healthcare sector rotation and earnings releases — the market is essentially ignoring this bill as legislative noise at this stage.
TIMELINE: The bill has been dormant for nearly five months. It needs committee markups in both Energy & Commerce and Ways & Means, House floor passage, Senate introduction/passage, and presidential signature. The effective date (2027) is still two years out. Near-term legislative probability is below 10%. This is a monitoring item, not a trading catalyst.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
Matched on shared policy language across AI analyses, with ticker & timing weight
PBM FAIR Act
To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes.
PBM Act
PBM Act
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →